{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T03:25:43Z","timestamp":1786937143185,"version":"build-2736575974"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":88,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"DOI":"10.1186\/s12951-026-04550-8","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T18:24:17Z","timestamp":1779387857000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["NK cell vesicles-based nanoplatform loaded with sorafenib synergizing ferroptosis and antitumor immunity against hepatocellular carcinoma"],"prefix":"10.1186","volume":"24","author":[{"given":"Chulan","family":"Gong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenjie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zailing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinlan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changya","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"issue":"3","key":"4550_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"4550_CR2","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12943-024-01988-y","volume":"23","author":"YT Chan","year":"2024","unstructured":"Chan YT, Wu J, Lu Y, Li Q, Feng Z, Xu L, et al. Loss of lncRNA LINC01056 leads to sorafenib resistance in HCC. Mol Cancer. 2024;23(1):74.","journal-title":"Mol Cancer"},{"issue":"1","key":"4550_CR3","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6.","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"4550_CR4","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","volume":"81","author":"EASL-EASD-EASO Clinical","year":"2024","unstructured":"EASL-EASD-EASO Clinical. Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492\u2013542.","journal-title":"J Hepatol"},{"issue":"3","key":"4550_CR5","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/ajg.2012.449","volume":"108","author":"AG Singal","year":"2013","unstructured":"Singal AG, Nehra M, Adams-Huet B, Yopp AC, Tiro JA, Marrero JA, et al. Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail? Am J Gastroenterol. 2013;108(3):425\u201332.","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"4550_CR6","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378\u201390.","journal-title":"N Engl J Med"},{"issue":"2","key":"4550_CR7","doi-asserted-by":"publisher","first-page":"e55945","DOI":"10.1371\/journal.pone.0055945","volume":"8","author":"QB Zhang","year":"2013","unstructured":"Zhang QB, Sun HC, Zhang KZ, Jia QA, Bu Y, Wang M, et al. Suppression of natural killer cells by sorafenib contributes to prometastatic effects in hepatocellular carcinoma. PLoS One. 2013;8(2):e55945.","journal-title":"PLoS One"},{"issue":"2","key":"4550_CR8","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41422-020-00441-1","volume":"31","author":"D Tang","year":"2021","unstructured":"Tang D, Chen X, Kang R, Kroemer G. Ferroptosis: molecular mechanisms and health implications. Cell Res. 2021;31(2):107\u201325.","journal-title":"Cell Res"},{"issue":"14","key":"4550_CR9","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1016\/j.cell.2022.06.003","volume":"185","author":"BR Stockwell","year":"2022","unstructured":"Stockwell BR. Ferroptosis turns 10: emerging mechanisms, physiological functions, and therapeutic applications. Cell. 2022;185(14):2401\u201321.","journal-title":"Cell"},{"issue":"1","key":"4550_CR10","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/s41392-021-00594-4","volume":"6","author":"J Xu","year":"2021","unstructured":"Xu J, Ji L, Ruan Y, Wan Z, Lin Z, Xia S, et al. UBQLN1 mediates sorafenib resistance through regulating mitochondrial biogenesis and ROS homeostasis by targeting PGC1\u03b2 in hepatocellular carcinoma. Signal Transduct Target Ther. 2021;6(1):190.","journal-title":"Signal Transduct Target Ther"},{"issue":"12","key":"4550_CR11","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1080\/15548627.2018.1503146","volume":"14","author":"Z Zhang","year":"2018","unstructured":"Zhang Z, Yao Z, Wang L, Ding H, Shao J, Chen A, et al. Activation of ferritinophagy is required for the RNA-binding protein ELAVL1\/HuR to regulate ferroptosis in hepatic stellate cells. Autophagy. 2018;14(12):2083\u2013103.","journal-title":"Autophagy"},{"issue":"11","key":"4550_CR12","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1038\/s41419-021-04342-y","volume":"12","author":"C Wang","year":"2021","unstructured":"Wang C, Zeng J, Li LJ, Xue M, He SL. Cdc25A inhibits autophagy-mediated ferroptosis by upregulating ErbB2 through PKM2 dephosphorylation in cervical cancer cells. Cell Death Dis. 2021;12(11):1055.","journal-title":"Cell Death Dis"},{"issue":"1","key":"4550_CR13","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41392-020-0187-x","volume":"5","author":"W Tang","year":"2020","unstructured":"Tang W, Chen Z, Zhang W, Cheng Y, Zhang B, Wu F, et al. The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects. Signal Transduct Target Ther. 2020;5(1):87.","journal-title":"Signal Transduct Target Ther"},{"issue":"7","key":"4550_CR14","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1002\/ijc.28159","volume":"133","author":"C Louandre","year":"2013","unstructured":"Louandre C, Ezzoukhry Z, Godin C, Barbare JC, Mazi\u00e8re JC, Chauffert B, et al. Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib. Int J Cancer. 2013;133(7):1732\u201342.","journal-title":"Int J Cancer"},{"issue":"8","key":"4550_CR15","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.7150\/ijbs.89942","volume":"20","author":"F Fontana","year":"2024","unstructured":"Fontana F, Giannitti G, Marchesi S, Limonta P. The PI3K\/Akt pathway and glucose metabolism: a dangerous liaison in cancer. Int J Biol Sci. 2024;20(8):3113\u201325.","journal-title":"Int J Biol Sci"},{"key":"4550_CR16","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.semcancer.2021.06.019","volume":"85","author":"L Yu","year":"2022","unstructured":"Yu L, Wei J, Liu P. Attacking the PI3K\/Akt\/mTOR signaling pathway for targeted therapeutic treatment in human cancer. Semin Cancer Biol. 2022;85:69\u201394.","journal-title":"Semin Cancer Biol"},{"issue":"7","key":"4550_CR17","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1002\/jcb.25091","volume":"116","author":"Z Liu","year":"2015","unstructured":"Liu Z, Zhu G, Getzenberg RH, Veltri RW. The upregulation of PI3K\/Akt and MAP kinase pathways is associated with resistance of microtubule-targeting drugs in prostate cancer. J Cell Biochem. 2015;116(7):1341\u20139.","journal-title":"J Cell Biochem"},{"issue":"4","key":"4550_CR18","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s10555-016-9637-x","volume":"35","author":"A Guerrero-Zotano","year":"2016","unstructured":"Guerrero-Zotano A, Mayer IA, Arteaga CL. PI3K\/AKT\/mTOR: role in breast cancer progression, drug resistance, and treatment. Cancer Metastasis Rev. 2016;35(4):515\u201324.","journal-title":"Cancer Metastasis Rev"},{"issue":"1","key":"4550_CR19","first-page":"358","volume":"17","author":"Q Li","year":"2018","unstructured":"Li Q, Lai Z, Yan Z, Peng J, Jin Y, Wei L, et al. Hedyotis diffusa Willd inhibits proliferation and induces apoptosis of 5\u2013FU resistant colorectal cancer cells by regulating the PI3K\/AKT signaling pathway. Mol Med Rep. 2018;17(1):358\u201365.","journal-title":"Mol Med Rep"},{"issue":"1","key":"4550_CR20","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1186\/s12882-025-04123-1","volume":"26","author":"Z Zhang","year":"2025","unstructured":"Zhang Z, Ma J, Shi M, Huang J, Xu Z. CIAPIN1 attenuates ferroptosis via regulating PI3K\/AKT pathway in LPS-induced podocytes. BMC Nephrol. 2025;26(1):201.","journal-title":"BMC Nephrol"},{"key":"4550_CR21","doi-asserted-by":"publisher","first-page":"155791","DOI":"10.1016\/j.phymed.2024.155791","volume":"132","author":"S Yan","year":"2024","unstructured":"Yan S, Bao S, Chen T, Chen J, Zhang J, Hu X, et al. Cinnamaldehyde alleviates aspirin-induced gastric mucosal injury by regulating pi3k\/akt pathway-mediated apoptosis, autophagy and ferroptosis. Phytomedicine. 2024;132:155791.","journal-title":"Phytomedicine"},{"key":"4550_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2025.156840","volume":"143","author":"J Zheng","year":"2025","unstructured":"Zheng J, Liu Y, Zhu F, Liu S, Cai Z, Liu M, et al. Picropodophyllin induces ferroptosis via blockage of AKT\/NRF2\/SLC7A11 and AKT\/NRF2\/SLC40A1 axes in hepatocellular carcinoma as a natural IGF1R inhibitor. Phytomedicine. 2025;143:156840.","journal-title":"Phytomedicine"},{"issue":"5","key":"4550_CR23","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/aps.2017.5","volume":"38","author":"YJ Zhu","year":"2017","unstructured":"Zhu YJ, Zheng B, Wang HY, Chen L. New knowledge of the mechanisms of sorafenib resistance in liver cancer. Acta Pharmacol Sin. 2017;38(5):614\u201322.","journal-title":"Acta Pharmacol Sin"},{"issue":"6","key":"4550_CR24","first-page":"9377","volume":"15","author":"H Zhang","year":"2018","unstructured":"Zhang H, Wang Q, Liu J, Cao H. Inhibition of the PI3K\/Akt signaling pathway reverses sorafenib-derived chemo-resistance in hepatocellular carcinoma. Oncol Lett. 2018;15(6):9377\u201384.","journal-title":"Oncol Lett"},{"issue":"6","key":"4550_CR25","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1158\/1535-7163.MCT-13-1043","volume":"13","author":"B Zhai","year":"2014","unstructured":"Zhai B, Hu F, Jiang X, Xu J, Zhao D, Liu B, et al. Inhibition of Akt reverses the acquired resistance to sorafenib by switching protective autophagy to autophagic cell death in hepatocellular carcinoma. Mol Cancer Ther. 2014;13(6):1589\u201398.","journal-title":"Mol Cancer Ther"},{"issue":"10","key":"4550_CR26","doi-asserted-by":"publisher","first-page":"752","DOI":"10.4254\/wjh.v6.i10.752","volume":"6","author":"TD Fischer","year":"2014","unstructured":"Fischer TD, Wang JH, Vlada A, Kim JS, Behrns KE. Role of autophagy in differential sensitivity of hepatocarcinoma cells to sorafenib. World J Hepatol. 2014;6(10):752\u20138.","journal-title":"World J Hepatol"},{"issue":"2","key":"4550_CR27","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41571-020-0426-7","volume":"18","author":"JA Myers","year":"2021","unstructured":"Myers JA, Miller JS. Exploring the NK cell platform for cancer immunotherapy. Nat Rev Clin Oncol. 2021;18(2):85\u2013100.","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"4550_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201907568","volume":"32","author":"S Gao","year":"2020","unstructured":"Gao S, Li T, Guo Y, Sun C, Xianyu B, Xu H. Selenium-containing nanoparticles combine the NK cells mediated immunotherapy with radiotherapy and chemotherapy. Adv Mater. 2020;32(12):e1907568.","journal-title":"Adv Mater"},{"key":"4550_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.879452","volume":"13","author":"WK Bae","year":"2022","unstructured":"Bae WK, Lee BC, Kim HJ, Lee JJ, Chung IJ, Cho SB, et al. A Phase I study of locoregional high-dose autologous natural killer cell therapy with hepatic arterial infusion chemotherapy in patients with locally advanced hepatocellular carcinoma. Front Immunol. 2022;13:879452.","journal-title":"Front Immunol"},{"issue":"4","key":"4550_CR30","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.20517\/evcna.2025.39","volume":"6","author":"N Amreddy","year":"2025","unstructured":"Amreddy N, Srivastava A, Riedinger N, Ragothaman M, Zhao YD, Gali H, et al. Tumor-targeted multifunctional extracellular vesicles as drug carriers for lung cancer therapy. Extracell Vesicles Circ Nucl Acids. 2025;6(4):1054\u201378.","journal-title":"Extracell Vesicles Circ Nucl Acids"},{"key":"4550_CR31","doi-asserted-by":"publisher","first-page":"10683","DOI":"10.2147\/IJN.S527756","volume":"20","author":"J Zhang","year":"2025","unstructured":"Zhang J, Guan W, Guo T, Zhang Y, Gong C, Ye R, et al. Comparison of the Cytotoxicity, Internalization and Anti-Cancer Drug Delivery Efficacy of Nature Killer Cell Derived Nanovesicles and Extracellular Vesicles. Int J Nanomed. 2025;20:10683\u2013700.","journal-title":"Int J Nanomed"},{"issue":"11","key":"4550_CR32","doi-asserted-by":"publisher","first-page":"5464","DOI":"10.7150\/thno.54822","volume":"11","author":"FH Kong","year":"2021","unstructured":"Kong FH, Ye QF, Miao XY, Liu X, Huang SQ, Xiong L, et al. Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma. Theranostics. 2021;11(11):5464\u201390.","journal-title":"Theranostics"},{"issue":"4","key":"4550_CR33","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1166\/jbn.2021.3061","volume":"17","author":"H Lai","year":"2021","unstructured":"Lai H, Zhong L, Huang Y, Zhao Y, Qian Z. Progress in application of nanotechnology in Sorafenib. J Biomed Nanotechnol. 2021;17(4):529\u201357.","journal-title":"J Biomed Nanotechnol"},{"issue":"10","key":"4550_CR34","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/nnano.2009.241","volume":"4","author":"K Kostarelos","year":"2009","unstructured":"Kostarelos K, Bianco A, Prato M. Promises, facts and challenges for carbon nanotubes in imaging and therapeutics. Nat Nanotechnol. 2009;4(10):627\u201333.","journal-title":"Nat Nanotechnol"},{"issue":"7","key":"4550_CR35","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s00204-011-0695-0","volume":"85","author":"A Hoshino","year":"2011","unstructured":"Hoshino A, Hanada S, Yamamoto K. Toxicity of nanocrystal quantum dots: The relevance of surface modifications. Arch Toxicol. 2011;85(7):707\u201320.","journal-title":"Arch Toxicol"},{"issue":"5685","key":"4550_CR36","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1126\/science.305.5685.762b","volume":"305","author":"F Proffitt","year":"2004","unstructured":"Proffitt F. Nanotechnology. Yellow light for nanotech. Science. 2004;305(5685):762.","journal-title":"Science"},{"key":"4550_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.biotechadv.2022.107983","volume":"59","author":"L Debbi","year":"2022","unstructured":"Debbi L, Guo S, Safina D, Levenberg S. Boosting extracellular vesicle secretion. Biotechnol Adv. 2022;59:107983.","journal-title":"Biotechnol Adv"},{"key":"4550_CR38","doi-asserted-by":"publisher","first-page":"1087689","DOI":"10.3389\/fimmu.2022.1087689","volume":"13","author":"H Luo","year":"2022","unstructured":"Luo H, Zhou Y, Zhang J, Zhang Y, Long S, Lin X, et al. NK cell-derived exosomes enhance the anti-tumor effects against ovarian cancer by delivering cisplatin and reactivating NK cell functions. Front Immunol. 2022;13:1087689.","journal-title":"Front Immunol"},{"key":"4550_CR39","doi-asserted-by":"publisher","first-page":"111632","DOI":"10.1016\/j.biopha.2021.111632","volume":"139","author":"M Ganesan","year":"2021","unstructured":"Ganesan M, Kanimozhi G, Pradhapsingh B, Khan HA, Alhomida AS, Ekhzaimy A, et al. Phytochemicals reverse P-glycoprotein mediated multidrug resistance via signal transduction pathways. Biomed Pharmacother. 2021;139:111632.","journal-title":"Biomed Pharmacother"},{"key":"4550_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.nano.2021.102494","volume":"40","author":"J Halder","year":"2022","unstructured":"Halder J, Pradhan D, Kar B, Ghosh G, Rath G. Nanotherapeutics approaches to overcome P-glycoprotein-mediated multi-drug resistance in cancer. Nanomedicine. 2022;40:102494.","journal-title":"Nanomedicine"},{"issue":"1","key":"4550_CR41","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41392-025-02312-w","volume":"10","author":"G Xu","year":"2025","unstructured":"Xu G, Jin J, Fu Z, Wang G, Lei X, Xu J, et al. Extracellular vesicle-based drug overview: research landscape, quality control and nonclinical evaluation strategies. Signal Transduct Target Ther. 2025;10(1):255.","journal-title":"Signal Transduct Target Ther"},{"issue":"17","key":"4550_CR42","doi-asserted-by":"publisher","first-page":"8185","DOI":"10.7150\/thno.59121","volume":"11","author":"J Du","year":"2021","unstructured":"Du J, Wan Z, Wang C, Lu F, Wei M, Wang D, et al. Designer exosomes for targeted and efficient ferroptosis induction in cancer via chemo-photodynamic therapy. Theranostics. 2021;11(17):8185\u201396.","journal-title":"Theranostics"},{"key":"4550_CR43","doi-asserted-by":"publisher","first-page":"118782","DOI":"10.1016\/j.ijpharm.2019.118782","volume":"572","author":"H Tang","year":"2019","unstructured":"Tang H, Chen D, Li C, Zheng C, Wu X, Zhang Y, et al. Dual GSH-exhausting sorafenib loaded manganese-silica nanodrugs for inducing the ferroptosis of hepatocellular carcinoma cells. Int J Pharm. 2019;572:118782.","journal-title":"Int J Pharm"},{"issue":"25","key":"4550_CR44","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202300319","volume":"12","author":"TB Gandek","year":"2023","unstructured":"Gandek TB, van der Koog L, Nagelkerke A. A comparison of cellular uptake mechanisms, delivery efficacy, and intracellular fate between liposomes and extracellular vesicles. Adv Healthc Mater. 2023;12(25):e2300319.","journal-title":"Adv Healthc Mater"},{"issue":"10","key":"4550_CR45","doi-asserted-by":"publisher","first-page":"859","DOI":"10.3109\/1061186X.2014.947295","volume":"22","author":"V Kaur","year":"2014","unstructured":"Kaur V, Garg T, Rath G, Goyal AK. Therapeutic potential of nanocarrier for overcoming to P-glycoprotein. J Drug Target. 2014;22(10):859\u201370.","journal-title":"J Drug Target"},{"issue":"7","key":"4550_CR46","doi-asserted-by":"publisher","first-page":"e0160042","DOI":"10.1371\/journal.pone.0160042","volume":"11","author":"F Li","year":"2016","unstructured":"Li F, Zhou X, Zhou H, Jia J, Li L, Zhai S, et al. Reducing both Pgp overexpression and drug efflux with anti-cancer Gold-Paclitaxel nanoconjugates. PLoS One. 2016;11(7):e0160042.","journal-title":"PLoS One"},{"issue":"35","key":"4550_CR47","doi-asserted-by":"publisher","first-page":"5352","DOI":"10.1039\/C9TB00541B","volume":"7","author":"B Zhang","year":"2019","unstructured":"Zhang B, Huang X, Wang H, Gou S. Promoting antitumor efficacy by suppressing hypoxia via nano self-assembly of two irinotecan-based dual drug conjugates having a HIF-1\u03b1 inhibitor. J Mater Chem B. 2019;7(35):5352\u201362.","journal-title":"J Mater Chem B"},{"issue":"1","key":"4550_CR48","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41392-024-01769-5","volume":"9","author":"Q Zhou","year":"2024","unstructured":"Zhou Q, Meng Y, Li D, Yao L, Le J, Liu Y, et al. Ferroptosis in cancer: From molecular mechanisms to therapeutic strategies. Signal Transduct Target Ther. 2024;9(1):55.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"4550_CR49","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s13046-021-02012-7","volume":"40","author":"J Yang","year":"2021","unstructured":"Yang J, Zhou Y, Xie S, Wang J, Li Z, Chen L, et al. Metformin induces Ferroptosis by inhibiting UFMylation of SLC7A11 in breast cancer. J Exp Clin Cancer Res. 2021;40(1):206.","journal-title":"J Exp Clin Cancer Res"},{"issue":"6","key":"4550_CR50","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41580-024-00703-5","volume":"25","author":"SJ Dixon","year":"2024","unstructured":"Dixon SJ, Olzmann JA. The cell biology of ferroptosis. Nat Rev Mol Cell Biol. 2024;25(6):424\u201342.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"8","key":"4550_CR51","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/s41419-023-06045-y","volume":"14","author":"Y Liu","year":"2023","unstructured":"Liu Y, Lu S, Wu LL, Yang L, Yang L, Wang J. The diversified role of mitochondria in ferroptosis in cancer. Cell Death Dis. 2023;14(8):519.","journal-title":"Cell Death Dis"},{"issue":"10","key":"4550_CR52","first-page":"3106","volume":"10","author":"W Lin","year":"2020","unstructured":"Lin W, Wang C, Liu G, Bi C, Wang X, Zhou Q, et al. SLC7A11\/xCT in cancer: biological functions and therapeutic implications. Am J Cancer Res. 2020;10(10):3106\u201326.","journal-title":"Am J Cancer Res"},{"key":"4550_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2022.115241","volume":"205","author":"J He","year":"2022","unstructured":"He J, Wang X, Chen K, Zhang M, Wang J. The amino acid transporter SLC7A11-mediated crosstalk implicated in cancer therapy and the tumor microenvironment. Biochem Pharmacol. 2022;205:115241.","journal-title":"Biochem Pharmacol"},{"key":"4550_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.116112","volume":"171","author":"X Xu","year":"2024","unstructured":"Xu X, Xu XD, Ma MQ, Liang Y, Cai YB, Zhu ZX, et al. The mechanisms of ferroptosis and its role in atherosclerosis. Biomed Pharmacother. 2024;171:116112.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"4550_CR55","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","volume":"22","author":"A Glaviano","year":"2023","unstructured":"Glaviano A, Foo ASC, Lam HY, Yap KCH, Jacot W, Jones RH, et al. PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer. 2023;22(1):138.","journal-title":"Mol Cancer"},{"key":"4550_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.semcancer.2019.12.008","volume":"80","author":"D Tewari","year":"2022","unstructured":"Tewari D, Patni P, Bishayee A, Sah AN, Bishayee A. Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: a novel therapeutic strategy. Semin Cancer Biol. 2022;80:1\u201317.","journal-title":"Semin Cancer Biol"},{"issue":"7","key":"4550_CR57","doi-asserted-by":"publisher","first-page":"111194","DOI":"10.1016\/j.celrep.2022.111194","volume":"40","author":"Y Sun","year":"2022","unstructured":"Sun Y, Zhang H, Meng J, Guo F, Ren D, Wu H, et al. S-palmitoylation of PCSK9 induces sorafenib resistance in liver cancer by activating the PI3K\/AKT pathway. Cell Rep. 2022;40(7):111194.","journal-title":"Cell Rep"},{"issue":"10","key":"4550_CR58","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001926corr1","volume":"9","author":"R Alzeibak","year":"2021","unstructured":"Alzeibak R, Mishchenko TA, Shilyagina NY, Balalaeva IV, Vedunova MV, Krysko DV. Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future. J Immunother Cancer. 2021;9(10):e001926corr1.","journal-title":"J Immunother Cancer"},{"issue":"5","key":"4550_CR59","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1016\/j.apsb.2025.03.016","volume":"15","author":"L Lin","year":"2025","unstructured":"Lin L, Fang Z, Liu G, Liu Y, Li Z, Pan D, et al. Prodrug-based combinational nanomedicine remodels lipid metabolism for reinforced ferroptosis and immune activation. Acta Pharm Sin B. 2025;15(5):2746\u201363.","journal-title":"Acta Pharm Sin B"},{"issue":"1","key":"4550_CR60","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12951-024-02297-8","volume":"22","author":"W Deng","year":"2024","unstructured":"Deng W, Shang H, Tong Y, Liu X, Huang Q, He Y, et al. The application of nanoparticles-based ferroptosis, pyroptosis and autophagy in cancer immunotherapy. J Nanobiotechnol. 2024;22(1):97.","journal-title":"J Nanobiotechnol"},{"issue":"12","key":"4550_CR61","doi-asserted-by":"publisher","first-page":"3414","DOI":"10.1016\/j.celrep.2017.11.079","volume":"21","author":"J Amores-Iniesta","year":"2017","unstructured":"Amores-Iniesta J, Barber\u00e0-Cremades M, Mart\u00ednez CM, Pons JA, Revilla-Nuin B, Mart\u00ednez-Alarc\u00f3n L, et al. Extracellular ATP activates the NLRP3 inflammasome and is an early danger signal of skin allograft rejection. Cell Rep. 2017;21(12):3414\u201326.","journal-title":"Cell Rep"},{"issue":"16","key":"4550_CR62","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202308316","volume":"11","author":"L Zhao","year":"2024","unstructured":"Zhao L, Chang F, Tong Y, Yin J, Xu J, Li H, et al. A multifunctional bimetallic nanoplatform for synergic local hyperthermia and chemotherapy targeting HER2-positive breast cancer. Adv Sci. 2024;11(16):e2308316.","journal-title":"Adv Sci"},{"issue":"13","key":"4550_CR63","doi-asserted-by":"publisher","first-page":"e2311529","DOI":"10.1002\/adma.202311529","volume":"36","author":"L Zuo","year":"2024","unstructured":"Zuo L, Ma Q, Xiao P, Guo Q, Xie W, Lu D, et al. Upgrading the Separators Integrated with Desolvation and Selective Deposition toward the Stable Lithium Metal Batteries. Adv Mater. 2024;36(13):e2311529.","journal-title":"Adv Mater"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-026-04550-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04550-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04550-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T03:12:20Z","timestamp":1786936340000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12951-026-04550-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4550"],"URL":"https:\/\/doi.org\/10.1186\/s12951-026-04550-8","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"assertion":[{"value":"18 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This animal experiment has been approved by the Ethics Committee of Guizhou Medical University, with approval number NO. 2502825.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"763"}}